VA Is Testing Semaglutide, a GLP-1 Drug, for Alcohol Use Disorder

Quick Answer

The report is real. The VA Office of Research and Development is sponsoring a large Phase 3 clinical trial of semaglutide, a GLP-1 medication, for veterans with moderate-to-severe alcohol use disorder.

The trial is called CRAVE, short for Cessation or Reduction of Alcohol Consumption in Veterans. It will compare weekly semaglutide injections with placebo and measure whether veterans have a clinically meaningful reduction in risky drinking.

This is important research. It is not proof that semaglutide treats alcohol use disorder. Semaglutide is not FDA-approved for alcohol use disorder, and the VA study had not yet begun recruiting according to its latest posted registry status.

“Alcoholism” is still a familiar term, but alcohol use disorder, or AUD, is the current clinical term. AUD can be mild, moderate, or severe. It is a medical condition, not a personal failure.

What the VA CRAVE Trial Will Test

The VA study is not a review of old medical records or a survey of veterans who already use GLP-1 drugs. It is an interventional Phase 3 clinical trial designed to test treatment effects directly.

The registry’s current structured enrollment field lists 622 participants. An older paragraph in the same record still says the study plans to randomize 438 veterans. This appears to be a registry-version inconsistency. The structured enrollment field is the more recently maintained study field, but the sponsor may clarify the final target in another update.

Who the Trial Is Designed For

The study plans to enroll veterans ages 18 through 80 who:

• Have moderate-to-severe alcohol use disorder
• Were recently drinking at a high or very high World Health Organization risk level
• Want to reduce their alcohol consumption
• Meet the study’s medical and safety requirements

The full eligibility list is extensive. It includes exclusions related to alcohol withdrawal severity, certain psychiatric conditions, pancreatitis, advanced liver disease, some diabetes treatments, pregnancy and other health factors. Eligibility can only be determined by the research team.

The trial record currently lists VA sites in California, Florida, Georgia, Illinois, Michigan, Minnesota, North Carolina, Ohio, Oregon, Pennsylvania, Texas, Utah, Washington and Wisconsin.

What Researchers Will Measure

CRAVE’s primary outcome is not simply whether someone reports “drinking less.” Researchers will assess whether participants achieve at least a two-level reduction in the World Health Organization risk-drinking category.

For example, moving from “very high risk” to “moderate risk” would meet that threshold. Drinking will be measured repeatedly with the Timeline Follow-Back, a structured calendar-based interview used in alcohol research.

Secondary outcomes include:

• The number of participants with no heavy-drinking days during the measured period
• Safety and adverse events
• Whether results differ by age, race, psychiatric conditions or other treatment
• Whether baseline impulsivity is associated with response

Participants are assigned to semaglutide or placebo in a 1:1 ratio. The registry says the dose can be increased gradually up to 2.4 mg weekly or the participant’s maximum tolerated dose. That is a research protocol—not dosing guidance for the public. A study team determines dosing and monitors participants.

Why Test a GLP-1 Drug for Alcohol Use Disorder?

Semaglutide is a GLP-1 receptor agonist. GLP-1 medications are known mainly for diabetes and weight management, but GLP-1 receptors are also present in brain regions involved in motivation and reward.

Animal studies, observational analyses and reports from people taking GLP-1 medications have suggested that these drugs may affect alcohol craving or consumption. Those findings cannot establish that the medication caused the change. Randomized trials are needed to separate a drug effect from weight loss, nausea, reduced appetite, behavioral support and other factors.

Several human trials now provide stronger evidence than anecdotes alone. The results are encouraging, but they are not uniformly positive across every outcome.

What Earlier Randomized Trials Found

2025 Injectable Semaglutide Pilot: 48 Participants

A Phase 2 randomized trial published in JAMA Psychiatry studied 48 adults with alcohol use disorder who were not seeking treatment. Participants received low-dose semaglutide, a GLP-1 drug, or placebo for nine weeks.

Semaglutide reduced alcohol consumed during a laboratory self-administration test. It also reduced drinks per drinking day and weekly craving and was associated with a greater decline in heavy drinking over time.

However, the trial did not find a significant effect on average drinks per calendar day or the number of drinking days. It was small, short and conducted at one academic center.

Source: Hendershot CS, et al. JAMA Psychiatry. 2025;82(4):395–405. doi:10.1001/jamapsychiatry.2024.4789; ClinicalTrials.gov NCT05520775

2026 Injectable Semaglutide Trial: 108 Participants

A randomized trial published in The Lancet enrolled 108 treatment-seeking adults with moderate-to-severe alcohol use disorder and obesity. Participants received weekly semaglutide, a GLP-1 medication, or placebo for 26 weeks. Both groups also received standard cognitive behavioral therapy.

Heavy-drinking days fell in both groups. The reduction was greater with semaglutide: the reported treatment difference was 13.7 percentage points. Gastrointestinal adverse effects occurred more often in the semaglutide group and were generally described as temporary and mild to moderate.

This was stronger evidence than the earlier pilot, but it was still a single-center study involving people who had both alcohol use disorder and obesity. The result may not apply equally to people without obesity or to veterans with different medical and psychiatric conditions.

Source: Klausen MK, et al. The Lancet. 2026;407(10540):1687–1698. doi:10.1016/S0140-6736(26)00305-3

2026 Oral Semaglutide Trial: 50 Participants

A Phase 2 trial published in The American Journal of Psychiatry studied 50 treatment-seeking adults with moderate-to-severe alcohol use disorder. Participants received oral semaglutide, a GLP-1 medication, or placebo for eight weeks.

The trial did not meet significant differences for its primary laboratory craving outcome or for drinks per day. It did report improvements in several secondary measures, including heavy-drinking days, drinks per drinking day, naturalistic craving and alcohol-related consequences.

This mixed result matters. A medication can appear promising on some outcomes while missing others. Larger, longer trials with predefined clinical endpoints are necessary before determining whether the overall benefit is meaningful.

Source: Schacht JP, et al. American Journal of Psychiatry. Published online July 29, 2026. doi:10.1176/appi.ajp.20260003

Why the VA Phase 3 Trial Matters

The VA trial is larger, longer and more geographically diverse than the early semaglutide studies. Its randomized placebo-controlled design can provide more reliable evidence about effectiveness and safety in veterans.

It may also answer practical questions that smaller studies could not:

• Does semaglutide produce a clinically meaningful reduction in risky drinking?
• Can participants remain on treatment long enough to benefit?
• How often do side effects lead to dose reduction or discontinuation?
• Are effects consistent across ages, racial groups and psychiatric histories?
• Does semaglutide add meaningful benefit beyond the improvement often seen with study participation and behavioral support?

A Phase 3 label does not mean the treatment already works. It describes the stage and scale of testing. Results will not be known until participants complete the study and the data are analyzed.

What the Trial Does Not Mean

The CRAVE trial does not mean:

• The VA has approved semaglutide for alcohol use disorder
• Ozempic is being prescribed as a standard VA alcoholism treatment
• Every GLP-1 medication has the same effect on alcohol use
• Reduced interest in alcohol while using a GLP-1 drug proves that AUD has been treated
• Someone should obtain or change a GLP-1 prescription to address drinking

The trial uses the generic drug semaglutide under a research protocol. Calling it an “Ozempic trial” would be misleading because Ozempic is a brand with specific approved indications, and the ClinicalTrials.gov record identifies the intervention as semaglutide.

Semaglutide Is Not an Approved AUD Treatment

No semaglutide product and no other GLP-1 medication is currently FDA-approved to treat alcohol use disorder.

Established care is available now. According to the National Institute on Alcohol Abuse and Alcoholism, treatment can include behavioral care, medications and mutual-support programs. Three medications are currently approved in the United States for alcohol use disorder: naltrexone, acamprosate and disulfiram. A doctor can help determine which options fit a person’s health, drinking pattern and treatment goals.

Source: NIAAA: Treatment for Alcohol Problems—Finding and Getting Help

People who may be physically dependent on alcohol should not abruptly stop without medical guidance. Alcohol withdrawal can become dangerous or life-threatening. Severe shaking, hallucinations, seizures, confusion or worsening withdrawal symptoms require urgent medical care.

How to Follow the VA Study

The most reliable source for recruitment and status changes is the live ClinicalTrials.gov CRAVE record.

As of the update posted July 23, 2026, the study was not yet recruiting, even though its estimated start date was July 28. Registry dates are estimates and can change. Veterans interested in the study should use the contacts and participating locations on the official record rather than responding to unofficial recruitment posts.

Results are not expected soon. The registry estimates primary completion in April 2028 and full study completion in May 2029. Publication and peer review would follow data collection and analysis.

The Bottom Line

The VA is genuinely launching a major study of semaglutide, a GLP-1 medication, for alcohol use disorder in veterans. CRAVE is a randomized Phase 3 trial designed to provide stronger evidence than anecdotes, medical-record associations or small pilot studies.

Earlier randomized trials suggest semaglutide may reduce some measures of craving and heavy drinking. They have also produced mixed results, involved selected populations and remained too small to establish semaglutide as standard care.

For now, semaglutide remains investigational for alcohol use disorder. People seeking help do not need to wait for the VA trial: evidence-based behavioral treatment and approved medications are already available through doctors and qualified treatment programs.

This article is for education only and does not replace medical advice. Do not start, stop or change a prescription medication based on early alcohol-use-disorder research. If alcohol withdrawal may be a concern, seek medical guidance before reducing or stopping alcohol use.

For treatment information, visit the NIAAA Alcohol Treatment Navigator. In the United States, the SAMHSA National Helpline is available at 1-800-662-4357.